Sooma Medical, a leading healthtech company, secures €5 million in new funding, bringing its total funding to €7.5 million.
- Key Investors: The funding round, spearheaded by Voima Ventures and backed by Verge HealthTech Fund and existing investor Stephen Industries, underscores confidence in Sooma’s transformative potential.
- Cutting-Edge Solution: Sooma’s claim to fame lies in its portable neuromodulation device that offers Transcranial Direct Current Stimulation (tDCS), a game-changer in alleviating depression symptoms.
- Accessible Treatment: Sooma’s therapy stands out as it’s one of the few that can be safely administered at home. Patients can opt for it as a standalone treatment or in conjunction with other therapies, providing flexibility and convenience.
- Future Expansion: Bolstered by the recent funding, Sooma aims to ramp up product development and further penetrate both existing and emerging markets, with a keen eye on the US market.
Sooma Medical’s journey marks a paradigm shift in combating depression globally, ushering in a new era of accessible, effective, and drug-free treatment options.
